Craig, Jessie et al, I have just returned from a month in India.
In that time Biota broke through the $2-00 support level and today went perilously close to the $1-00 support level ($1-025) before finishing at $1-09.
It could have been worse but it was certainly not "a great day for Biota stock holders".
I remain very positive about Biota because all I read indicates that Tamiflu is dead in the water for Swine Flu (and any subsequent Flu Strains)and Relenza and LANI remain the last line of defence if the vaccines provide inadequate protection.
Biota and GSK have communication/transparency problems that are having aajor impact on the BTA share price. BTA management MUST address this.
Absence of a dividend makes it unattractive to the vast majority of investors.
The declining AU$ may help the earnings significantly (depending on timing).
Governments around the world are now short of cash and they have had their fingers burnt by vaccines and Tamiflu - but they still have to manage the influenza risk and that will mean demand for Relenza/Lani (review of stockpiles will be longer term than previously thought).
The retail market for Relenza in Japan and pootentially elsewhere for Swine Flu and/or Seasonal Flu is virtually unlimited.
I/V Relenza trials are underway and will hopefully demonstrate the life-saving outcomes for influenza patients in intensive care.
Now is a great buying opportunity.
No debt.
Cash in the bank.
A monopoly on effective antivirals.
More developments in the pipeline.
Swine Flu has not gone away.
Where is the management PR strategy?
BTA has been crucified.
Hang in there.
LOL DYOR
Regards
Kangaroo1
BTA Price at posting:
$1.09 Sentiment: Hold Disclosure: Held
